Aron Kandinov, MD, will join the group’s Williamsburg, Brooklyn office, located at 101 Broadway, effective September 1, 2022.

We are so pleased that Dr. Kandinov will be joining the ENTA Family. He will provide convenient access to Ear, Nose, and Throat care at a time where there is such a need, and our patients can look forward to receiving the best treatment from him.

TARRYTOWN, N.Y. (PRWEB)
November 22, 2021

ENT and Allergy Associates, LLP (ENTA) recognizes that in order to provide the best ear, nose, throat, and allergy care throughout New York and New Jersey, it must continue to attract and recruit the most qualified and experienced specialists coming out of training today. With that in mind, ENTA is pleased to announce that Rutgers trained otolaryngologist Aron Kandinov, MD, will join the group’s Williamsburg, Brooklyn office, located at 101 Broadway, effective September 1, 2022.

The addition of Dr. Kandinov expands the ENTA’s roster of ENT specialists and sub-specialists in the region. With four clinical locations throughout the borough, the practice can provide Brooklyn residents with same day, high quality care that has not previously been available in the area.

Dr. Kandinov will treat both adult and pediatric patients, while offering a complete range of in-office otolaryngology care and services.

Dr. Kandinov earned Bachelor of Science degrees in Microbiology/Immunology, as well as French and Francophone Studies, from the University of Michigan. He went on to graduate with his medical doctorate from Wayne State University School of Medicine in Detroit, Michigan, and will be completing his ENT residency at Rutgers New Jersey Medical School in June 2022. He is a member of the Academy of Otolaryngology-Head and Neck Surgery, the American Medical Association, and the Triological Society.

In Williamsburg, Dr. Kandinov will serve the needs of patients alongside an elite clinical team, including otolaryngologist Neil Prufer, MD (Fellowship trained in Laryngology) and allergist/immunologist Ujwala Kaza, MD, FACAAI, FAAAAI.

“With the addition of Dr. Kandinov, we have further augmented the high-quality care we provide to the Williamsburg community,” said Neil Prufer, MD. “I am very happy to welcome Dr. Kandinov to our team of experienced and well-trained physicians.”

“We are so pleased that Dr. Kandinov will be joining the ENTA Family,” said Robert Glazer, CEO of ENTA. “He will provide convenient access to Ear, Nose, and Throat care at a time where there is such a need, and our patients can look forward to receiving the best treatment from him. We welcome him with open arms.”

“Dr. Kandinov is a well-rounded addition to our growing practice,” said Steven Gold, MD, Vice President of ENTA and Chair of the ENTA Recruitment Committee. “With his arrival, the communities of Brooklyn will have even more access to top notch physicians. As we continue to grow, we intend to bring more specialists to local communities so patients can receive world-class care right in their own neighborhood.”

To learn more about the benefits of ENT and Allergy Associates, find the office near you or book an appointment, please visit http://www.entandallergy.com or call 1-855-ENTA-DOC.

About ENT and Allergy Associates, LLP:

ENT and Allergy Associates LLP (ENTA) has more than 220 physicians practicing in 44 office locations in Westchester, Putnam, Orange, Dutchess, Rockland, Nassau, and Suffolk counties, as well as New York City and northern/central New Jersey. The practice sees over 90,000 patients per month. Each ENTA clinical location provides access to a full complement of services, including General Adult and Pediatric ENT and Allergy, Voice and Swallowing, Advanced Sinus and Skull Base Surgery, Facial Plastics and Reconstructive Surgery, Disorders of the Inner Ear and Dizziness, Asthma, Clinical Immunology, Diagnostic Audiology, Hearing Aid dispensing, Sleep and CT Services. ENTA has clinical alliances with Mount Sinai Hospital, Montefiore Medical Center, Northwell Health, Saint Barnabas Medical Center, and a partnership with the American Cancer Society.

Share article on social media or email:

Dr. Peiman Soleymani’s oral health practice treats patients from the Westside and all of Greater Los Angeles.

Gum disease is nothing to shrug off and proper periodontal care is a must.

LOS ANGELES (PRWEB)
November 22, 2021

An October 20 article on Express reports on a pair of Harvard studies that found a strong link between a patient’s history of gum disease and a higher chance of developing esophageal or gastric cancer. The two studies together looked at a sample size of 150,000 participants, noting that patients in the study who had gum disease had a 43% higher chance of esophageal cancer and a 52% higher chance of stomach cancer than those without that history. Oral health clinic Beverly Hills Periodontics & Dental Implant Center says that the study results highlight that, whatever else may be true, gum disease is nothing to shrug off and proper periodontal care is a must.

The West Los Angeles area clinic says periodontal disease has already been tied to many serious health conditions such as heart disease, diabetes, and Alzheimer’s. Nevertheless, the addition of certain types of cancers only strengthens the point that seeking treatment for any stage of gum disease should be a priority for patients. Without periodontal disease treatment, the early stages of gum disease can rapidly develop into periodontitis and, if that is left untreated, tooth loss.

The oral health center notes that the most obvious symptoms of gum disease include bleeding gums, especially when eating, brushing, or flossing; recessed gums, swelling, pus, loose teeth, and chronic oral pain or discomfort. However, the center also says that gum disease can progress without any notable symptoms until it reaches an advanced stage. As such, the center says it’s exceedingly important to have a specialist check a patient’s teeth and gums periodically to make sure no hidden ailments are developing.

Beverly Hills Periodontics & Dental Implant Center says that treatment for periodontal diseases tends to vary by patient, but generally starts with scaling and root planning – sometimes referred to as deep cleaning. This procedure, the center continues, involves thoroughly disinfecting pockets and surfaces of the oral cavity to significantly reduce the amount of harmful bacteria. The surfaces of teeth are also smoothed out to make it harder for bacteria and other contaminants to take hold, limiting the chances of a resurgence of the disease. In milder cases, this treatment combined with good oral hygiene is enough to arrest the problem. However, when the problem is more advance, numerous more advanced methods are available and can lead to positive outcomes in most cases.

Readers can learn more about Beverly Hills Periodontics & Dental Implant Center by visiting their website at https://www.bhperiodontist.com/ or calling (310) 275-4606.

Share article on social media or email:

A recent study shows that about 85 percent of clinical trials of new drugs and medical devices will experience delays, and over 90 percent of them for a month or longer.

The solution to [clinical trial delays] … lies in the adoption of a cloud-based decentralized platform approach. Rather than tether patients to a central, usually urban medical facility, a decentralized clinical trial enables bi-directional communication between study sites and participants.

TYSONS CORNER, Va. (PRWEB)
November 22, 2021

A recent study shows that about 85 percent of clinical trials of new drugs and medical devices will experience delays, and over 90 percent of them for a month or longer. The cost of these delays to the developer run between approximately $600,000 and $8 million per day.(1) “While this is bad news for the pharmaceutical industry, not to mention patients hoping for new treatments, it is also a wakeup call,” says Dr. Harsha Rajasimha, founder and CEO of Jeeva(TM) Informatics. “Today’s technology and near-universal digital accessibility, offer ways to significantly lessen delays—and possibly costs—in clinical trials.”

In addition to delays, says Dr. Rajasimha, the traditional approach to clinical trial structure and management tends to discourage patient diversity. Chief among the many reasons for this is the fact that trials are held in a limited number of large metropolitan cities, study protocol logistics are suboptimal for the participants concerned with missing work and finding childcare, and because of a lack of information. Patients who participate in these studies skew heavily white—in some cases, 80 to 90 percent.(2) Noting that November is Pancreatic Cancer and Lung Cancer Awareness Month(3), he points out that though people of color have a statistically greater disposition toward pancreatic cancer, they are under-represented in clinical trials for treatments of this life-threatening disease.(4)

This sort of under-representation, says Dr. Sharlene Brown, Jeeva Informatics Director of Business Development, can be traced to the narrow pool from which clinical trial participants tend to be drawn. In one case, she recalls encountering a patient foundation leader charged with explaining to veteran trial operators why a proposed site in Vermont—a state in which white people make up 94.2% of the population(5)—would be less successful at recruiting local participants living with sickle cell disease—a disease that in the U.S. most commonly affects people of color.(6) In a broader sense, adds Dr. Rajasimha, recruitment problems are a leading cause of delays in clinical trials. Earlier this year, approximately 1,000 organizations involved in medical research announced delays or disruption in planned clinical trials, the bulk of them caused either by slow enrollment(7) or complex data handling issues(8).

The solution to these problems, he suggests, and with it the potential for reduced delays and greater study effectiveness, lies in the adoption of a cloud-based decentralized clinical trial platform approach. Rather than tether prospective patients to a central, usually urban medical facility, a decentralized clinical trial enables bi-directional communication between study sites and participants, primarily through the Internet. If empowered by the right bring-your-own-device (BYOD) eClinical platform, anyone with access to a cell phone, or a tablet, or a PC, can use it to interact with the study investigator teams by video, telemedicine, SMS, or email. Among other benefits, says Dr. Rajasimha, this approach enables sponsors to increase both diversity and enrollment by recruiting through social media platforms.

Some of these needed changes in clinical trials, notes Dr. Rajasimha, have been accelerated by the COVID-19 pandemic, which has made many prospective enrollees unable or unwilling to travel to a hospital or other major medical facility, to participate in a new drug study. At the same time, the pandemic has strained the ability of hospitals to deal with swelling crowds of severely ill patients, let alone simultaneously administering a non-COVID19 clinical trial. In response, many trial sponsors have begun adopting a decentralized structure out of necessity.

Dr. Rajasimha hopes that this trend will continue. “Whatever we do,” he says, “we must not go back but forward.” Across the board, decentralizing clinical studies is an important part of the solution for delayed and under-enrolled clinical trials. Medical research is, he notes, in the end about patients—about people. “For the clinical trial process to live up to its own expectations, we must go where the people are, and communicate with them—and they with us—in the most effective way possible.”

About Jeeva Informatics

The personal experience of losing a child born with a rare disease and a brother with a chronic disease became the springboard for Dr. Harsha Rajasimha to apply his years of postdoctoral training at NIH and FDA to accelerate therapies for rare and common conditions. He knew that technology in itself is not the limiting factor and that patient-centered design guided by stakeholder needs and regulatory requirements would guide their continuous learning digital platform. By digitizing and automating manual repetitive tasks and reducing the logistical burdens on patients and study teams by over 70%, Jeeva accelerates the process of bringing new medicines or vaccines to patients who need them by over 3x faster. The Virginia-based company’s modular software-as-a-service platform is fully scalable and facilitates patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device. Visit https://jeevatrials.com/

1.    “How to Avoid Costly Clinical Research Delays: Blog.” MESM, mesm.com/blog/tips-to-help-you-avoid-costly-clinical-research-delays/.

2.    “Clinical Trials Have Far Too Little Racial and Ethnic Diversity.” Scientific American, 1 Sept. 2018, scientificamerican.com/article/clinical-trials-have-far-too-little-racial-and-ethnic-diversity/#:~:text

3.    “November Is Pancreatic Cancer Awareness Month.” Hirshberg Foundation for Pancreatic Cancer Research, 22 Oct. 2021, pancreatic.org/november/.

4.    “Lack of Diversity in Pancreatic Cancer Trials.” Cure Today, 26 Aug. 2021, curetoday.com/view/lack-of-diversity-in-pancreatic-cancer-trials.

5.    U.S. Census Bureau Quickfacts: Vermont. census.gov/quickfacts/VT

6.    “Data & Statistics on Sickle Cell Disease.” Centers for Disease Control and Prevention, 16 Dec. 2020, cdc.gov/ncbddd/sicklecell/data.html#:~:text

7.    Healthcare, GlobalData. “Disrupted Clinical Trials Due to Slow Recruitment Continue to Rise.” Clinical Trials Arena, clinicaltrialsarena.com/comment/disrupted-clinical-trials-slow-recruitment/.

8.    “Data Delays – a Real-Time Challenge for Clinical Trials in Pharma.” Six Degrees Medical, 17 Sept. 2020, sixdegreesmed.com/data-delays-challenge-clinical-trials-pharma/.

Share article on social media or email:

Hushabye Nursery logo

PHOENIX (PRWEB)
November 22, 2021

The Bob & Renee Parsons Foundation granted $250,000 to Hushabye Nursery in support of its inpatient detox nursery and recovery center for infants experiencing Neonatal Abstinence Syndrome (NAS). Hushabye Nursery provides a therapeutic environment, short-term medical care and social services for infants suffering from NAS, along with outpatient services and resources for families experiencing opioid use disorder (OUD). NAS affects newborn babies who were exposed to opioids in the womb and requires a complex and painful detoxification process in the days following birth. According to the American Academy of Pediatrics (AAP), in the United States, a baby is born every 15 minutes with NAS resulting from prenatal opioid exposure.

“The team at Hushabye Nursery is providing a new level of compassionate care to substance-exposed infants,” said President and Executive Creative Director of PXG Apparel Renee Parsons. “The organization is giving these babies and their families hope, and the tools they need to move forward.”

Hushabye Nursery’s approach is distinctly different than the typical hospital neonatal intensive care unit. Hushabye Nursery provides a comfortable, safe environment – with quiet, private rooms and dim lighting – for babies to be cared for as they go through detox. While hospitals treat NAS babies primarily with medication, Hushabye resorts to drugs only when necessary. Hushabye’s approach has lowered treatment time during this painful period to an average of only six days compared to an average of 16 to 21 days in traditional hospital neonatal ICUs.

“Created by nurse practitioners, Hushabye Nursery is one of only three nationwide medical care models dedicated to treating infants experiencing Neonatal Abstinence Syndrome,” said Hushabye Nursery executive director and founder Tara Sundem. “Thanks to generous donors like Bob and Renee Parsons, we are able to support and comfort babies through the withdrawal process and offer moms and dads who are in recovery a nonjudgmental place to develop a long term plan for treatment and keeping their family safe.”

Hushabye Nursery takes a holistic approach to treating babies born with NAS and supporting their families by offering behavioral health and educational resources. In addition to the nursery, Hushabye offers wraparound services, including both prenatal and postnatal programs. Even after a baby is discharged, the organization helps coordinate long-term care such as pediatric support, counseling and OUD treatment, as well as recovery and prevention programs.

“The harsh reality is the infants being cared for by Hushabye Nursery are born addicted to opioids and suffering the excruciatingly painful process of withdrawal,” said PXG Founder and CEO Bob Parsons. “The loving care Hushabye extends, along with social services and family support, sets a foundation for these children to have some chance for a better future.”

The Covid-19 pandemic exacerbated opioid use disorder and it is estimated that one in eight children ages 17 or younger resided in households with at least one parent who had a substance use disorder (SUD) in the past year. The prevalence of OUD within families underscores the need for Hushabye Nursery’s comprehensive approach to OUD prevention, one that treats the entire family, is community-based and culturally informed and addresses the traumatic experiences that may accompany substance use. This integration of healthcare and social services helps keep children safely with their families instead of being separated during recovery, mitigating the impact of adverse childhood experiences on families. To learn more about the organization or how to get involved, please visit the Hushabye Nursery website at http://www.hushabyenursery.org.

About Hushabye Nursery

Hushabye Nursery is an intermediate residential medically observed recovery center for Neonatal Abstinence Syndrome. Hushabye Nursery was formed in response to the emerging crisis of substance-exposed infants. Hushabye Nursery will provide these infants with a quiet, loving, therapeutic environment while they recover from intense withdrawal symptoms. Hushabye Nursery is committed to providing families with the support they need to successfully navigate the road of recovery. This work will include prenatal, postnatal care, and support after discharge for the transition to home.

About The Bob & Renee Parsons Foundation

The Bob & Renee Parsons Foundation offers support to nonprofit organizations successfully working to empower, educate, nurture, and nourish people during what is often the darkest time of their lives. Founded in 2012 by philanthropists and business leaders Bob and Renee Parsons to provide hope and life-changing assistance to the country’s most vulnerable populations, The Bob & Renee Parsons Foundation offers critical funding at critical times to those in need. The Foundation’s giving is driven by the core belief that all people – regardless of race, religion, roots, economic status, sexual orientation, or gender identity – deserve access to quality healthcare, education and a safe place to call home. Follow @WeDealInHope on social media or visit TBRPF.org to learn more about partner organizations and the important work being done in the community.

# # #

Share article on social media or email:

Mindray

Mindray will be returning to the show floor in Chicago, IL, for RSNA’s 107th Scientific Assembly and Annual Meeting Nov. 28 – Dec. 2. All RSNA attendees are invited to visit Mindray exhibit #6716 in the North Hall to explore innovative ultrasound solutions and connect with the Mindray Team.

MAHWAH, N.J. (PRWEB)
November 22, 2021

Mindray, a global leader and developer of healthcare technologies and solutions for ultrasound, patient monitoring, and anesthesia, announced they will be returning to the show floor in Chicago, IL, for the Radiological Society of North America’s (RSNA) 107th Scientific Assembly and Annual Meeting taking place November 28 – December 2. All RSNA attendees are invited to visit Mindray exhibit #6716 in the North Hall to explore innovative ultrasound solutions, connect with the Mindray Team, and check out the immersive and interactive virtual reality (VR) experience.

Mindray has worked diligently to establish itself as a global leader, developing meaningful ultrasound solutions to help clinicians provide timely answers and elevate patient care. They have a rich history of innovation that has disrupted the industry and changed how ultrasound is utilized. From creating the industry’s first virtual beamforming architecture and breaking the barriers of conventional ultrasound imaging to safeguarding their ultrasound systems with an industry-leading total cost of ownership, and unrivaled peace of mind investment protection program, Mindray has proven that innovation is at the core of all they do.

“We are continually pushing towards our vision of better healthcare for all. Our team and solutions have been disrupting the industry for the past 30 years, and we don’t plan on stopping anytime soon,” said Mindray’s Sr. Director of Marketing, Ultrasound, Maher Elhihi. Elhihi continued, “our unique, groundbreaking and cost-effective ultrasound machines enable clinicians to remain at the cutting-edge of imaging for years to come; this has become increasingly critical due to today’s rapidly changing healthcare environment. Clinicians are facing issues they’ve never seen before, and with uncertainty becoming the norm, our goal is to give them some peace of mind.”    

The following systems will be highlighted in Mindray exhibit #6716, with live scanning educational sessions featured throughout the meeting:                                 

• Resona 7 Ultrasound System | Lightning Edition: Mindray’s flagship premium System, the Resona 7, delivers crystal clear and uniform imaging across a wide variety of exams and provides the details needed for a confident diagnosis without the need for additional imaging modalities. With the highly anticipated launch of the Resona 7 Lightning Edition, Mindray is slated to take the Radiology Ultrasound market “by storm” at RSNA.
• DC-90 Ultrasound System with X-Insight: Mindray’s DC-90 Ultrasound is a versatile, high-performing System designed for a comprehensive range of clinical applications. With an easy-to-position monitor, an ultra-slim multi-gesture touchscreen, and five active transducer ports, the DC-90 refines user experience with a flexible and intuitive design to deliver high-efficiency and dynamic performance with intelligent, precise, and clear imaging.
• TE7 Max Ultrasound Machine: Mindray’s newest ultrasound machine, the TE7 Max, provides best-in-class image quality, a superior user experience during clinical assessments and procedures, and an extensive suite of artificial intelligence (AI) powered Smart Tools. Ideal for use in Interventional Radiology, the TE7 Max is equipped with advanced needle enhancement technologies like iNeedle+TM. This second-generation iNeedle+ technology automatically detects the angle of incidence and improves visibility on both linear and convex transducers during interventional procedures.

With over 30 years of experience, Mindray has brought numerous innovative ultrasound solutions to the market. As the developer of the first software-based beamformer technology – ZONE Sonography® Technology+ (ZST+), Mindray’s unique approach provides clinicians with higher frame rates, decreased motion artifacts, and a precise display of hemodynamics, giving users clear, uniform images – regardless of body habitus. Mindray invites all RSNA attendees to stop by exhibit #6716 and see how innovative, cost-effective, leading-edge ultrasound solutions can empower Radiology Departments to provide the highest quality of care now and in the future.

Share article on social media or email: